Clinical trial Recruiting at 1 site Interventional Ages 3 to 16

Speech therapy for kids with rare genetic conditions and childhood apraxia of speech

Official title: A Single Case Experimental Design Study of Motor Speech Treatment for Children With Childhood Apraxia of Speech and Rare Genetic Conditions

Run by Murdoch Childrens Research Institute · NCT07815249 · Data updated 2026-11-12

This study tests whether 4 weeks of targeted speech therapy can improve speech accuracy in children with childhood apraxia of speech and rare genetic conditions, using one treatment approach per child.

More Apraxia of Speech trials

Quick facts

Study typeInterventional
Ages3 Years to 16 Years
SexAll
Enrollment20 (estimated)
SponsorMurdoch Childrens Research Institute
Academic / other
Locations1 site (Melbourne, Victoria)
StatusRecruiting
StartedJuly 1, 2026
Main results expectedDecember 2027
Study endsDecember 2028
Registry record updatedSeptember 11, 2026
Trial IDNCT07815249 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children aged 3 to 16 years with a confirmed genetic condition and a diagnosis of childhood apraxia of speech, who speak English at home and can participate in therapy 3 times per week for 4 weeks.

Probably not a fit

Children who cannot participate for 45 minutes, have difficulty sustaining attention, or have conditions that prevent engagement with the therapy may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-case experimental design study assigns each child to one of two motor speech therapies, DTTC or ReST, based on age and speech abilities. Participants receive baseline probes, a 4-week treatment block with three therapy sessions per week, and follow-up probes at 1, 4, and 8 weeks to track changes in trained speech targets, generalisation to untrained targets, intelligibility, and functional communication. Repeated measures during baseline, treatment, and follow-up assess level, trend, and maintenance of change. The primary goal is to determine whether the chosen therapy improves accuracy for trained targets in children with CAS and a rare genetic condition, with secondary aims exploring untrained targets, overall intelligibility, and everyday communication per parent report.

Why it matters

Potential benefit: If successful, the trial could show that tailored speech therapy improves speech accuracy and everyday communication for children with CAS and genetic conditions.

How similar studies have gone: Prior work supports the use of DTTC and ReST in improving speech in CAS, though research in the context of rare genetic conditions is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Children aged between 3 and 16 years, with a confirmed genetic condition and a diagnosis of childhood apraxia of speech; English as the primary language at home; able to participate in speech therapy 3 times per week for 4 weeks

Exclusion Criteria:

* Diagnosis of an acquired brain or movement condition likely to affect speech; currently receiving motor speech therapy in the community; diagnosis of a behavioural condition likely to impact engagement (i.e., unable to participate for 45 minutes, unable to focus attention at the speech therapist's face for a few minutes at a time, unable to say any sounds and/or use gesture, unable to try to copy speech therapist; intolerant to touch (if touch cues are needed for DTTC)

Where it's running

  • Murdoch Children's Research Institute
    Melbourne, Victoria, Australia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.